This news for Regen describes the approach of developing a cellular product for isolating immune cells and re-programming to attack tumor cells for humans. This has been demonstrated to work. This was also the approach mentioned previously for canines. Two and two?
SAN DIEGO, February 24, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach. Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug Application (IND) with the FDA for testing of this approach in cancer patients. Dr. Kesari is Director of Neuro-Oncology, Professor of Neurosciences and Chairman of the Department of Translational Neuro-Oncology and Neuro-Therapeutics at the John Wayne Cancer Center.
The experiments revealed that administration of Regen's proprietary gene silencing compounds triggered cells of the immune system to profoundly produce growth factors such as interleukin-17 and interleukin-18. These factors are critical to inducing an anticancer immune response. The company is currently developing a cellular product that involves extraction of a small amount of patient blood, isolating specific immune cells from the blood, gene-silencing the NR2F6 target in the extracted immune cells, and subsequently re-administering the immune cells. The goal is to "reprogram" the immune cells to attack tumors.
"As an oncologist, I have witnessed firsthand the powerful effects of immune stimulatory drugs called checkpoint inhibitors that have recently entered the market. The experiments completed in our collaboration strongly suggest that NR2F6, Regen's drug target, acts as one of the immunological checkpoints. We are excited to partner with Regen in bringing this new means of stimulating the immune system to patients," said Dr. Kesari.
AI
